Pharma Pioneer

Corbus Commences U.S. Phase 1 Trial with First Patient Dosed for Next-Gen Nectin-4 ADC CRB-701

17 May 2024
2 min read

Corbus Pharmaceuticals, a precision oncology firm, has initiated a Phase 1 clinical trial in the U.S. for CRB-701 (SYS6002), an innovative antibody-drug conjugate (ADC) that targets Nectin-4, a protein overexpressed in certain cancers. The trial is designed to assess the safety, efficacy, and pharmacokinetics of CRB-701 in patients with advanced solid tumors characterized by high Nectin-4 expression. The study will begin with dose escalation, proceed to dose optimization, and culminate in dose expansion to establish the dosage for Phase 2 trials.
The trial's commencement follows positive preliminary data from a Phase 1 study conducted by CSPC Pharmaceutical Group in China, suggesting that CRB-701 may offer a distinct pharmacokinetic and safety profile compared to PADCEV® (enfortumab vedotin-ejfv), a currently approved Nectin-4 ADC for metastatic urothelial cancer. The potential benefits of CRB-701 are particularly relevant for patients with metastatic urothelial cancer and other Nectin-4 positive tumors.
CRB-701 is equipped with a site-specific, cleavable linker and a uniform drug-to-antibody ratio of 2, utilizing monomethyl auristatin E (MMAE) as its cytotoxic payload. Nectin-4 is a well-established tumor-associated antigen in urothelial cancer, and PADCEV® has recently been expanded for use in combination with KEYTRUDA® for patients who are not candidates for cisplatin-based chemotherapy.
Corbus Pharmaceuticals, headquartered in Norwood, Massachusetts, is dedicated to advancing innovative scientific methods to combat serious illnesses through a diverse portfolio. Their pipeline includes CRB-701, CRB-601, an anti-integrin monoclonal antibody targeting TGFβ on cancer cells, and CRB-913, a CB1 inverse agonist for obesity treatment.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Verve Therapeutics Pauses Gene-Editing Clinical Trial Following Patient's Adverse Reaction
Pharma Pioneer
2 min read
Verve Therapeutics Pauses Gene-Editing Clinical Trial Following Patient's Adverse Reaction
17 May 2024
A clinical trial for a gene-editing treatment by Verve Therapeutics, known as VERVE-101, has been halted after a participant experienced severe side effects.
Read →
Ractigen Commences Phase I Clinical Trial with First Patient Treated for NMIBC Using RAG-01
Pharma Pioneer
2 min read
Ractigen Commences Phase I Clinical Trial with First Patient Treated for NMIBC Using RAG-01
17 May 2024
In a significant medical advancement, Ractigen Therapeutics has initiated its first-ever human clinical trial for RAG-01, a novel small activating RNA (saRNA) treatment for NMIBC.
Read →
Verismo Submits FDA Application for IND Approval of SynKIR™-310 for Treating Recurrent or Refractory B-cell NHL
Pharma Pioneer
2 min read
Verismo Submits FDA Application for IND Approval of SynKIR™-310 for Treating Recurrent or Refractory B-cell NHL
17 May 2024
Verismo Therapeutics, a company specializing in CAR T-cell therapies, is progressing with its second clinical trial using the SynKIR™ platform.
Read →
Preliminary Phase 1/2 Clinical Trial Results for mRNA-3927, a Potential mRNA Treatment for Propionic Acidemia, Featured in Nature Journal
Pharma Pioneer
2 min read
Preliminary Phase 1/2 Clinical Trial Results for mRNA-3927, a Potential mRNA Treatment for Propionic Acidemia, Featured in Nature Journal
17 May 2024
Moderna, a biotechnology company, has reported preliminary results from a phase 1/2 clinical trial for mRNA-3927.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.